Pacira BioSciences, Inc. (NASDAQ:PCRX) Director Marcelo Bigal Acquires 1,512 Shares

Pacira BioSciences, Inc. (NASDAQ:PCRX) Director Marcelo Bigal bought 1,512 shares of the company’s stock in a transaction dated Friday, August 16th. The stock was bought at an average cost of $13.25 per share, with a total value of $20,034.00. Following the transaction, the director now directly owns 10,142 shares in the company, valued at approximately $134,381.50. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Pacira BioSciences Stock Performance

Shares of PCRX opened at $13.89 on Wednesday. The company has a debt-to-equity ratio of 0.67, a quick ratio of 5.70 and a current ratio of 6.82. Pacira BioSciences, Inc. has a 1 year low of $11.16 and a 1 year high of $38.23. The firm has a fifty day moving average of $21.68 and a 200-day moving average of $26.42. The company has a market cap of $646.52 million, a price-to-earnings ratio of 9.71 and a beta of 0.88.

Pacira BioSciences (NASDAQ:PCRX) last posted its earnings results on Tuesday, July 30th. The company reported $0.64 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.53 by $0.11. Pacira BioSciences had a net margin of 9.21% and a return on equity of 13.22%. The firm had revenue of $178.02 million during the quarter, compared to analyst estimates of $173.31 million. As a group, equities analysts anticipate that Pacira BioSciences, Inc. will post 2.22 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on the company. Piper Sandler downgraded Pacira BioSciences from an “overweight” rating to a “neutral” rating and decreased their price target for the stock from $42.00 to $11.00 in a research note on Monday, August 12th. StockNews.com downgraded Pacira BioSciences from a “strong-buy” rating to a “buy” rating in a report on Monday, August 12th. Truist Financial cut Pacira BioSciences from a “buy” rating to a “sell” rating and reduced their price objective for the stock from $30.00 to $8.00 in a research note on Tuesday, August 13th. Barclays lowered shares of Pacira BioSciences from an “overweight” rating to an “equal weight” rating and lowered their target price for the company from $38.00 to $25.00 in a research note on Wednesday, July 3rd. Finally, Royal Bank of Canada cut shares of Pacira BioSciences from an “outperform” rating to a “sector perform” rating and dropped their target price for the stock from $37.00 to $14.00 in a report on Monday, August 12th. Two research analysts have rated the stock with a sell rating, four have issued a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $24.78.

Hedge Funds Weigh In On Pacira BioSciences

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. ICA Group Wealth Management LLC bought a new stake in Pacira BioSciences during the 4th quarter valued at $30,000. GAMMA Investing LLC increased its holdings in shares of Pacira BioSciences by 229.6% during the second quarter. GAMMA Investing LLC now owns 1,338 shares of the company’s stock valued at $38,000 after purchasing an additional 932 shares during the period. Park Place Capital Corp bought a new stake in shares of Pacira BioSciences during the second quarter valued at about $46,000. Innealta Capital LLC acquired a new stake in Pacira BioSciences in the second quarter worth about $50,000. Finally, nVerses Capital LLC lifted its holdings in Pacira BioSciences by 800.0% in the second quarter. nVerses Capital LLC now owns 1,800 shares of the company’s stock worth $51,000 after purchasing an additional 1,600 shares during the period. 99.73% of the stock is owned by institutional investors.

Pacira BioSciences Company Profile

Pacira BioSciences, Inc engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature to targeted nerves.